Results 101 to 110 of about 40,526 (207)

Analysis of Anti-Xa Concentrations in Patients on Treatment Dose Enoxaparin: a Retrospective Chart Review [PDF]

, 2013
The purpose of this retrospective chart review was to determine the correlation between full weight-based enoxaparin use and the frequency of anti-Xa concentrations within the defined therapeutic range; to ascertain if anti-Xa monitoring is being ...
Angelotti, Erik, Levine, Lauren, Pallme, Nicole, Shiltz, Dane L.   +3 more
core   +1 more source

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications

Clinical Pharmacology: Advances and Applications, 2018
Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jerash University,
Tahaineh L, Edaily SM, Gharaibeh SF
doaj  

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement

Thrombosis Journal, 2011
Background Patients undergoing elective total hip replacement (THR) surgery are at an increased risk for venous thromboembolic events (VTEs). Dalteparin and enoxaparin are recommended as thromboprophylaxis for at least 10 days in these patients.
Choe Yoonhee, Jelincic Valentina, Dranitsaris George   +2 more
doaj   +1 more source

Evaluating Anti-factor Xa Levels in Patients with Augmented Renal Clearance Receiving Enoxaparin Prophylaxis: An Exploratory Pilot Study

Journal of Research in Pharmacy Practice
Objective: Anticoagulation therapy, including enoxaparin, is crucial for preventing blood clots in patients at risk for thromboembolic events. However, due to enoxaparin’s enhanced renal elimination, proper prophylactic dosing may be challenging.
Zahra Sahraei, Azadeh Eshraghi, Saghar Barati   +2 more
doaj   +1 more source

Characterization of PCL and Chitosan Nanoparticles as Carriers of Enoxaparin and Its Antithrombotic Effect in Animal Models of Venous Thrombosis

Journal of Nanotechnology, 2017
This study was based on the preparation, characterization, and animal in vivo experiments performed to evaluate nanoparticles of poly(ɛ-caprolactone) (PCL) and chitosan as carriers of enoxaparin.
Lucas Bessa Prado, Stephany Cares Huber, Aline Barnabé, Fernanda Dutra Santiago Bassora, Devanira Souza Paixão, Nelson Duran, Joyce Maria Annichino-Bizzacchi   +6 more
doaj   +1 more source

Effectiveness of enoxaparin in preventing intraoperative fibrin formation during DMEK assessed in a before-and-after study

Scientific Reports
To demonstrate that enoxaparin in the irrigation saline solution can effectively prevent intraoperative fibrin formation (IFF) during Descemet membrane endothelial keratoplasty (DMEK) surgery without compromising graft viability, visual recovery, or ...
Pablo De-Arriba-Palomero, David Mingo-Botín, Jaime Etxebarría-Ecenarro, Javier Celis, María Teresa Merino-Diez, Cristina García-Tomás, Martha Stokking, Juan Álvarez de Toledo, Francisco J. Muñoz-Negrete, Francisco Arnalich-Montiel   +9 more
doaj   +1 more source

Consumption pattern of enoxaparin in a non-teaching hospital (a cross-sectional prospective study)

Journal of Pharmacoeconomics and Pharmaceutical Management, 2022
Background: Drug use evaluation studies are conducted to assess the pattern of prescribing and administration of a drug. Deep vein thrombosis is one of the most important clinical issues around the world.
Mohammadreza Rafati, Shahram Ala, Mahsa Heydari, Bita Lashto-Aghaee   +3 more
doaj  

Post‐Varicella Purpura Fulminans With Extensive Skin Necrosis in a Child

eJHaem, Volume 7, Issue 1, February 2026.
Madalena Correia Pires, Ana Costa e Castro, Filipa Marujo, Rita Valsassina, Joana Patena Forte, Joana de Pais de Faria   +5 more
wiley   +1 more source

A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease [PDF]

, 2005
Background It is well described that diabetes mellitus is a hypercoagulable state. It is also known that patients with renal dysfunction have impaired platelet aggregation and function.
Brophy, Donald F., Carr, Marcus E., Gehr, Todd W. B., Martin, Erika J.   +3 more
core   +1 more source

The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism [PDF]

, 2008
Muir, K.W.
core   +1 more source